BioNTech (NASDAQ:BNTX) Reaches New 12-Month Low After Analyst Downgrade

BioNTech SE Sponsored ADR (NASDAQ:BNTX)’s share price hit a new 52-week low during trading on Tuesday after Citigroup lowered their price target on the stock from $145.00 to $130.00. Citigroup currently has a buy rating on the stock. BioNTech traded as low as $79.52 and last traded at $81.4570, with a volume of 4313149 shares traded. The stock had previously closed at $102.16.

Other equities analysts have also issued reports about the stock. UBS Group upgraded shares of BioNTech to a “hold” rating in a research note on Thursday, December 4th. Bank of America restated a “buy” rating and set a $128.00 price objective on shares of BioNTech in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Jefferies Financial Group dropped their target price on shares of BioNTech from $151.00 to $138.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, TD Cowen cut their price target on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research note on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $133.73.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS -$0.39 vs -$0.57 expected; revenue ~$1.06B vs $942M expected); management highlighted a strong cash position and multiple upcoming late‑stage readouts. Earnings Press Release
• Positive Sentiment: Analysts remain generally constructive: Canaccord reaffirmed a Buy with a $171 PT and Goldman Sachs also reaffirmed Buy — these positive analyst stances can support near‑term buying interest. Canaccord Note
• Neutral Sentiment: BioNTech announced plans to contribute certain rights/technologies to a new independent company led by co‑founders; BioNTech will retain a minority stake and may receive milestones/royalties — could free focus/resources but adds execution complexity. Company Release
• Neutral Sentiment: Reported short‑interest data in March shows zero shares (likely a reporting/data anomaly) — not meaningful for sentiment at this time.
• Negative Sentiment: Co‑founders Prof. Ugur Sahin and Prof. Özlem Türeci plan to leave by end of 2026 to launch a new mRNA company — markets view founder exits as a governance and execution risk, which triggered heavy selling. Reuters
• Negative Sentiment: FY‑2026 revenue guidance was lowered materially (company now sees ~€2.0–2.3B vs consensus nearer €3.1B) — the weaker outlook is a primary driver of the recent selloff. Full Results & Guidance
• Negative Sentiment: Multiple outlets reported a steep one‑day stock drop after the earnings/guidance and founder news; several brokers have cut price targets (Jefferies, Citigroup, BMO lowered PTs; TD Cowen moved to Hold) — analyst downgrades/PT cuts amplify downside pressure. Analyst Notes Summary
• Negative Sentiment: Investor litigation/claims firm Johnson Fistel announced an inquiry into potential shareholder claims related to executive actions — adds legal/ reputational overhang. Johnson Fistel Notice

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. Dodge & Cox lifted its position in BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after purchasing an additional 2,769,654 shares during the period. BNP Paribas Financial Markets boosted its holdings in BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares in the last quarter. GSK plc acquired a new position in BioNTech during the 4th quarter worth approximately $84,711,000. Franklin Resources Inc. raised its stake in shares of BioNTech by 76.8% during the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock worth $80,065,000 after buying an additional 326,556 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of BioNTech by 5.6% during the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock worth $72,517,000 after buying an additional 35,958 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Up 8.3%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. The firm has a market capitalization of $20.46 billion, a price-to-earnings ratio of -17.34 and a beta of 1.51. The firm has a fifty day moving average price of $106.64 and a 200 day moving average price of $102.75.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.